Home »
Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

Double click on above image to view full picture

Email to a Colleague - Print - Fax Order

Additional Information

Price	$3,500.00
Publisher	GBI Research
Date of Report	Jan 7, 2011

Add to Wishlist | Add to Compare

Qty:

-OR-

Quick Overview

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

Summary

GBI Research’s report, “Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles and to Create Opportunities for Growth”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes -
- Annualized market data for the kidney and renal diseases therapeutics market from 2001 to 2010, forecast forward to 2017
- Analysis of the leading therapeutic segments.
- Analysis of the kidney and renal diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the kidney and renal diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2010 in the global kidney and renal diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 GBI Research Report Guidance 11
3 Kidney and Renal Diseases Therapeutics Market to 2017: Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for the Global Kidney and Renal Disease Market 13
3.2.1 Revenue 13
3.2.2 Annual Cost of Treatment (ACT) 14
3.3 Treatment Usage Patterns 15
3.3.1 Diseased Population 17
3.3.2 Treatment Seeking Population 18
3.3.3 Diagnosis Population 19
3.3.4 Prescription Population 20
4 Kidney and Renal Diseases Therapeutics Market to 2017: Geographical Landscape 21
4.1 Revenue Analysis by Geography 21
4.2 The US 23
4.2.1 Revenue 23
4.2.2 Annual Cost of Treatment 24
4.3 Top Five Countries of Europe 25
4.3.1 Revenue 25
4.3.2 Annual Cost of Treatment 26
4.4 Japan 27
4.4.1 Revenue 27
4.4.2 Annual Cost of Treatment 28
5 Kidney and Renal Diseases Therapeutics Market to 2017: Therapeutic Landscape 29
5.1 Chronic Kidney Diseases Market 29
5.1.1 Introduction 29
5.1.2 Revenue 30
5.1.3 Annual Cost of Treatment 32
5.1.4 Treatment Usage Patterns 33
5.1.5 Drivers and Barriers for the Chronic Kidney Diseases Market 39
5.1.6 Drivers for the Chronic Kidney Disease Market 39
5.1.7 Barriers for the Chronic Kidney Disease Market 39
5.2 Renal Anemia Market 40
5.2.1 Introduction 40
5.2.2 Revenue 40
5.2.3 Annual Cost of Treatment 43
5.2.4 Treatment Usage Patterns 44
5.2.5 Drivers and Barriers for the Renal Anemia Market 50
5.2.6 Drivers for the Renal Anemia Market 51
5.2.7 Barriers for the Renal Anemia Market 51
5.3 Diabetic Nephropathy Market 52
5.3.1 Introduction 52
5.3.2 Revenue 52
5.3.3 Annual Cost of Treatment 55
5.3.4 Treatment Usage Patterns 56
5.3.5 Drivers and Barriers for the Diabetic Nephropathy Market 61
5.3.6 Drivers for the Diabetic Nephropathy Market 61
5.3.7 Barriers for the Diabetic Nephropathy Market 61
5.4 Acute Kidney Injury Market 62
5.4.1 Introduction 62
5.4.2 Revenue 63
5.4.3 Annual Cost of Treatment 65
5.4.4 Treatment Usage Patterns 67
5.4.5 Drivers and Barriers for the Acute Kidney Injury Market 73
5.4.6 Drivers for the Acute Kidney Injury Market 73
5.4.7 Barriers for the Acute Kidney Injury Nephropathy Market 73
6 Kidney and Renal Diseases Therapeutics Market to 2017 – Product Pipeline Analysis 74
6.1 Introduction 74
6.1.1 Research and Development Pipeline – Chronic Kidney Disease (CKD) 75
6.1.2 Research and Development Pipeline – Renal Anemia (RA) 81
6.1.3 Research and Development Pipeline – Diabetic Nephropathy (DN) 83
6.1.4 Research and Development Pipeline – Acute Kidney Injury (AKI) 86
6.2 Profiles of Promising Drugs in the Kidney and Renal Disease Market 89
6.2.1 AMG 223 89
6.2.2 AST-120 90
6.2.3 CellCept 90
6.2.4 Ferinject 91
6.2.5 Genz-644470 92
6.2.6 Hematide 93
6.2.7 HEPLISAV 93
6.2.8 Heptar 94
6.2.9 SBR759 95
6.2.10 Sulodexide 96
6.2.11 YM533 96
6.2.12 Zuragen 97
6.2.13 Olmetec 97
7 Kidney and Renal Diseases Therapeutics Market to 2017 – Competitive Landscape 99
7.1 Market Share Analysis 99
7.2 Amgen Inc. 100
7.2.1 Company Overview 100
7.2.2 Business Overview 100
7.2.3 SWOT Analysis 101
7.3 Merck & Co., Inc. 102
7.3.1 Company Overview 102
7.3.2 Business Overview 102
7.3.3 SWOT Analysis 103
7.4 Bristol-Myers Squibb Company 104
7.4.1 Company Overview 104
7.4.2 Business Overview 104
7.4.3 SWOT Analysis 105
7.5 Hoffmann-La Roche Inc. 106
7.5.1 Company Overview 106
7.5.2 Business Overview 106
7.5.3 SWOT Analysis 107
7.6 Shire Inc. 108
7.6.1 Company Overview 108
7.6.2 Business Overview 108
7.6.3 SWOT Analysis 109
8 Kidney and Renal Diseases Therapeutics Market to 2017 – M&A Landscape 110
8.1 M&A Deals 110
8.1.1 Deal Summary 111
8.1.2 Deals by Geography 113
8.2 Licensing Deals 114
8.2.1 Summary of Licensing Deals (2009-2010) 115
8.3 Co-development Deals 117
8.3.1 Summary of Co-development Deals (2009-2010) 118
9 Kidney and Renal Diseases Therapeutics Market to 2017 – Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 122
9.3.3 Primary Research 122
9.3.4 Expert Panel Validation 124
9.4 Contact Us 124
9.5 Disclaimer 124
9.6 Sources 124